- Home
- PBR vs REGN Comparison
PBR vs REGN Comparison
Compare PBR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBR
- REGN
- Stock Information
- Founded
- PBR 1953
- REGN 1988
- Country
- PBR Brazil
- REGN United States
- Employees
- PBR N/A
- REGN N/A
- Industry
- PBR Oil & Gas Production
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PBR Energy
- REGN Health Care
- Exchange
- PBR Nasdaq
- REGN Nasdaq
- Market Cap
- PBR 74.8B
- REGN 63.4B
- IPO Year
- PBR N/A
- REGN 1991
- Fundamental
- Price
- PBR $13.05
- REGN $511.20
- Analyst Decision
- PBR Strong Buy
- REGN Buy
- Analyst Count
- PBR 7
- REGN 23
- Target Price
- PBR $17.97
- REGN $854.26
- AVG Volume (30 Days)
- PBR 24.3M
- REGN 1.5M
- Earning Date
- PBR 08-07-2025
- REGN 07-31-2025
- Dividend Yield
- PBR 15.11%
- REGN 0.34%
- EPS Growth
- PBR N/A
- REGN 16.49
- EPS
- PBR 0.65
- REGN 39.43
- Revenue
- PBR $86,553,065,075.00
- REGN $14,085,700,000.00
- Revenue This Year
- PBR N/A
- REGN N/A
- Revenue Next Year
- PBR $0.61
- REGN $6.83
- P/E Ratio
- PBR $9.66
- REGN $13.03
- Revenue Growth
- PBR 1.14
- REGN 7.52
- 52 Week Low
- PBR $11.03
- REGN $476.49
- 52 Week High
- PBR $15.73
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- PBR 71.54
- REGN 41.90
- Support Level
- PBR $11.04
- REGN $503.25
- Resistance Level
- PBR $13.23
- REGN $538.20
- Average True Range (ATR)
- PBR 0.32
- REGN 15.52
- MACD
- PBR 0.20
- REGN 1.72
- Stochastic Oscillator
- PBR 99.10
- REGN 58.56
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2024 was 2.7 million barrels of oil equivalent a day (80% oil production), and reserves stood at 10.9 billion boe (85% oil). At end-2023, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).